The Rise of the Biotech Studio: TCG Labs Soleil Advances Three Clinical Assets

SAN FRANCISCO – October 28, 2026 — In an era defined by capital constraints and a relentless biopharma demand for immediate clinical validation, the traditional biotechnology startup model is undergoing a radical structural shift. The days of funding sprawling, cash-burning platform companies are increasingly giving way to the "biotech studio"—a venture-creation model designed for ruthless capital efficiency and asset-centric de-risking.

Today, TCG Labs Soleil provided a compelling operational proof-of-concept for this new paradigm. The venture-biotech organization, launched in 2024 in collaboration with The Column Group, announced that three of its independent, single-asset portfolio companies have initiated first-in-human Phase 1 clinical trials across oncology and cardiovascular disease. A fourth candidate is slated to enter the clinic later this year.

Advancing three novel molecular entities into human trials within approximately two years of corporate launch is an aggressive timeline that highlights the productivity of a centralized research and development engine.

"TCG Labs Soleil selectively advances therapeutic programs from translational development and up to early clinical proof-of-concept," said Jin-Long Chen, Ph.D., Managing Partner of TCG Labs and Chief Executive Officer of Soleil. "Since our launch in 2024, our centralized in-house R&D hub has rapidly built a deep portfolio that now includes 19 portfolio companies. The advancement of three molecules into Phase 1 clinical trials represents the first wave of our clinical portfolio."

The Asset-Centric De-risking Engine

The strategic architecture of TCG Labs Soleil pairs a dedicated venture fund with an evergreen, in-house R&D hub. Rather than building a single company with a pipeline of multiple drugs, the firm incubates discoveries internally and spins them out into independent, single-asset subsidiaries.

According to venture analysts tracking the life sciences sector, this single-asset structure provides a frictionless path to liquidity. By isolating assets in independent corporate vehicles, the firm creates bespoke acquisition targets for large pharmaceutical companies looking to backfill looming patent cliffs, entirely bypassing the baggage of acquiring an overarching platform or redundant pipeline assets.

The model relies heavily on generating meaningful early clinical evidence before pursuing strategic biopharma partnerships. By absorbing the translational and early clinical risk internally, TCG Labs Soleil aims to command premium valuations once clinical proof-of-concept is established.

Cracking Solid Tumor Selectivity with Precision Engagers

The first two clinical assets emerging from the Soleil hub are taking aim at one of oncology's most notoriously difficult challenges: making bispecific T-cell engagers work in solid tumors. While these therapies have revolutionized the treatment of hematological malignancies, their application in solid tumors has been severely limited by on-target, off-tumor toxicities—essentially, the immune system attacking healthy tissue that shares antigens with the tumor.

Duboce Biopharmaceuticals, a TCG Labs Soleil company, has initiated a Phase 1a/1b trial for DBC-664. The investigational therapy is an ALPP/L2 x CD3 T-cell engager aimed at solid tumors expressing ALPP or ALPPL2, with a specific focus on ovarian and endometrial cancers. Because these tumor-associated antigens have highly restricted expression patterns in healthy tissue, Duboce is betting that DBC-664 can widen the therapeutic window, safely directing T-cells to eradicate the tumor without triggering systemic autoimmune damage.

Similarly, Juri Biosciences is tackling metastatic prostate cancer with JUR-003, a KLK2-directed T-cell engager now in a Phase 1a/1b dose-escalation study. KLK2 is a serine protease whose expression is tightly restricted to prostate tissue and heavily upregulated in prostate cancer cells. Preclinical data linked to the asset's early development suggests that targeting KLK2 yields potent tumor-cell killing with significantly lower cytokine release compared to earlier-generation CD3-directed therapies—a critical differentiation point for patient safety.

Interestingly, while the company envisions JUR-003 as a subcutaneously administered therapy—a profile highly desirable for long-term treatment in earlier disease settings—current clinical trial registries indicate that the initial Phase 1 dose escalation is utilizing intravenous administration. The transition to a subcutaneous formulation will likely be a key value inflection point for Juri Biosciences as the asset matures.

The High-Stakes Factor XI Arena

Beyond oncology, TCG Labs Soleil is aggressively positioning itself in the highly competitive cardiovascular space. Arguello Biosciences has initiated a Phase 1 single-ascending dose trial in healthy adults for ARG-397, a half-life-extended Factor XI monoclonal antibody designed for durable anticoagulation in thromboembolic disorders like atrial fibrillation.

The race to develop Factor XI and XIa inhibitors represents the holy grail of modern cardiology: achieving robust anticoagulation to prevent strokes and clots without increasing the risk of catastrophic bleeding. By inhibiting Factor XI, these drugs target the intrinsic coagulation pathway responsible for pathological clot formation while preserving the extrinsic pathway required for normal hemostasis.

Arguello is entering an arena dominated by heavyweights. Bayer is currently advancing its oral Factor XIa inhibitor, asundexian, in Phase 3 trials, while Bristol Myers Squibb and Janssen are pushing forward with their own oral candidate, milvexian.

However, Arguello's strategic differentiator lies in its modality. As a half-life-extended antibody, ARG-397 is designed for infrequent dosing—potentially once monthly or less. This positions the asset closely against Anthos Therapeutics' abelacimab, another long-acting antibody that has demonstrated remarkably low bleeding rates in early trials. If ARG-397 can validate its safety profile and extended dosing interval in human trials, it could capture a significant niche among patients who struggle with the daily adherence required by current direct oral anticoagulants.

Expanding the Horizon: Respiratory Inflammation

Rounding out the portfolio's near-term clinical momentum is Clement Therapeutics, which recently completed IND-enabling studies for CMT-133. Slated to enter first-in-human trials later this year, CMT-133 is a bispecific antibody targeting alpha-TSLP and alpha-IL-33, two upstream alarmins heavily implicated in the inflammatory cascade of respiratory diseases.

By dual-targeting these pathways, Clement is designing a therapy intended to treat both Type 2 high and Type 2 low patient populations suffering from chronic obstructive pulmonary disease (COPD) and severe asthma. The approach underscores TCG Labs Soleil's broader strategy: identifying validated biological targets, engineering highly specific molecular interventions, and rapidly forcing the asset through the crucible of early clinical testing.